All News
The RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read Article
RWCS Meeting Begins Today
The 11th annual meeting of the Rheumatology Winter Clinical Symposium (RWCS) begins today (2/7) and runs through Saturday (2/10) and features a premiere faculty delivering state-of-the-art lectures.
Read Article
Biosimilar Reports - February 2018
Biosimilars command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. The global biosimilar market is expected to reach $36 billion USD by 2022. Here is this month's roundup of clinical trials and journal articles, overviews/reviews, practice and physician attitudes, and regulatory and pharma news - all on the subject of biosimilars.
Read Article
Top 10 MMWR CDC Reports from 2017
Here are the 10 most talked about MMWR Reports of 2017.
Read Article
The RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read Article
Rheumatology Physician Burnout and Depression
The 2018 Medscape Physician Burnout and Depression report shows that 42% of physician respondents report "burnout" and up to 15% experience some sort of depression. In a survey of 15,543 doctors from 29 specialties, they found highest burnout rates in critical care and neurologists (48%), family medicine (47%), ob/gyns and internists (46%). Lowest rates were seen in pathology and dermatology (32%), and plastic surgery (23%).
What did rheumatologists report?
Read Article
Prevalence of Arthritis Grossly Underestimated
Researchers at the Boston University School of Medicine have published a new report showing that arthritis affected 91 million adults in the US in 2015 or 37% of the poplulation. Their prevalence estimate is 68% higher than previously reported arthritis national estimates.
Read Article
Gout Associated with Work Absenteeism
Annals of Rheumatic Disease reports that gout is associated with higher work absenteeism and thus, increased costs for society due to productivity loss.
Read Article
Health Economics of SLE
A number of presentations over the past few days have addressed the health economics of SLE.
Read Article
CDC Endorses New Shingles Vaccine Over Zostavax
The U.S. Centers for Disease Control (CDC) announced on 25 October they endorsed the use of the new GSK shingles vaccine (Shingrix) over the currently available live-virus vaccine (Zostavax) from Merck.
Read Article
Top 16 Drugs in Rheumatology 2016
Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum). Highlights from this report include:
Read Article
Biosimilars Projected to Yield $54 Billion in Savings
A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers.
Read Article
Rheumatologists are Slow to Change DMARDs
The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment. Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months.
Read Article
Arthritis Burden over $303 Billion Annually in U.S.
Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.
Read Article
The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read Article
29 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.
Read Article
CDC: 40% of U.S Adults Claim to Have Arthritis
The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.
Read Article
Sarcoid and Rheumatoid Arthritis Risk Increased by Silica Exposure
A Swedish study has shown that occupational silica exposure increases the incidence rates of sarcoidosis and rheumatoid arthritis (RA) in those exposed workers in Swedish iron foundries.
Read Article
No Evidence to Support Use of Gabapentinoids in Low Back Pain
Management of chronic low back pain (CLBP) is often complex, requiring multiple modalities and meds to control pain. An analysis of studies shows that Gabapentinoids, including pregabalin and gabapentin, have little to no benefits but significant risk of adverse effects.
Read Article